Abstract
We analyzed outcome in a group patients who recieved very high CD34 cell dose (≥20 × 106 CD34 cells/kg)(Group A). We compared this, with a group of patients who recieved between 3–10 × 106 CD34 cells/kg (Group B). There was no significant difference between the groups in recipient age, gender, disease risk or reciept of sex mismatched product. The donor characteristics were also similar between both groups except for CD34 cell doses which was 30.1 ± 10.2 cells/kg in group A and 6.2 ± 2 cells/kg in group B (p < 0.000001). The dose of CD3, CD4, CD8, CD19 and CD16/56 subset of cells were also significantly higher in group A than in group B. All but 10 patients in group A recieved a similar conditioning regimen and all but 5 in group A recieved GVHD prophylaxis with single agent cyclosporine. Eight patients in group A recieved alternative ablative conditioning regimens and 2 recieved reduced intensity conditioning regimens. Five patients in group A also recieved methotrexate for GVHD prophylaxis.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
